Fatal toxic epidermal necrolysis-like lupus after longitudinally extensive transverse myelitis, vasculitic neuropathy and myositis despite reassuring serology: a case report

Systemic lupus erythematosus is a condition where the body's immune system, which usually acts as a shield against infection, mistakenly turns against its own tissues. It is a disease of many faces, capable of attacking the skin, kidneys, joints, and brain. Doctors have long relied on specific chemical signals in the blood to track how active the disease is. The most trusted of these signals are antibodies that target the body's own genetic material and proteins that help clean up cellular debris. When these markers are high, the disease is usually flaring; when they are low, the disease is thought to be quiet. However, this reliance on blood tests has a blind spot. The standard tools used to measure disease activity were designed primarily to watch the kidneys, and they often fail to notice when the disease is quietly destroying the spinal cord, nerves, or muscles, even when the blood tests look perfectly normal.

This story begins with a thirty-year-old woman in Kolkata, India, who had been managing her lupus and kidney disease with medication for less than a year. She was stable until she began experiencing strange episodes that looked like seizures, along with visual hallucinations and weakness in her legs. Within a month, her condition worsened dramatically. Her spinal cord became inflamed over a long stretch, causing her to lose all movement in her legs and control of her bladder. At the same time, the nerves in her body began to fail, her muscles became inflamed and damaged, and her bone marrow stopped producing enough blood cells. Despite receiving powerful treatments, including high-dose steroids and a series of monthly infusions designed to reset the immune system, she never regained the use of her legs. She remained permanently paralyzed from the waist down.

What made this case so difficult to understand was that her blood tests told a different story than her body. As the doctors administered the strong immune-suppressing drugs, the chemical markers that usually signal a lupus flare dropped to normal levels. Her genetic-targeting antibodies became undetectable, and the proteins that help clear cellular waste returned to a healthy range. By the numbers, she should have been getting better. Yet, her body continued to deteriorate. The disease had simply moved to a different part of her body, attacking the spinal cord and nerves in a way that the standard blood tests could not see. The very tools meant to reassure her doctors were actually hiding the severity of her condition.

Two months after her final round of intensive treatment, a new and terrifying crisis emerged. Her skin began to change. It started with ring-shaped red patches that quickly spread and merged. Within five days, the top layer of her skin began to separate from the layers beneath it, a reaction known as a positive Nikolsky sign, where the skin slips away with the slightest touch. This detachment covered more than half of her entire body, including her legs, arms, torso, and face, leaving her raw and vulnerable. While she had mild irritation inside her mouth, the damage was almost entirely on the outside. The doctors faced a critical decision: was this a reaction to a new medication, or was it a rare, life-threatening form of the lupus itself?

To answer this, the medical team had to rule out the most common cause of such skin failure: a severe reaction to a drug. They looked back at every medicine she had taken in the two months before the skin started to peel. She had not started any new drugs. The medications she was taking, including the one used to maintain her condition, had been part of her routine for months or years without causing problems. The timeline did not fit a drug reaction. They also considered infections, but tests for common viruses that cause blistering skin were negative. The bacteria found in her blood later turned out to be a consequence of her skin barrier breaking down, not the cause of the rash. With drug reactions and infections ruled out, and given that her skin had started with a ring-shaped pattern typical of lupus, the doctors concluded this was a rare manifestation of her underlying disease, a condition where the skin dies off in a way that mimics a severe drug reaction.

The situation became critical because her body was already weakened. Her bone marrow, which had been suppressed by her earlier treatments, could not mount a strong defense. Her skin, which normally acts as a wall against the outside world, was gone over more than half her body. In a healthy person, a massive infection like the one she developed would cause a high fever and a rapid rise in white blood cells. But in her case, the signs were almost invisible. She had only a slight fever and a very small increase in white blood cells, even though her blood was filled with multiple types of bacteria and yeast. Her body was too exhausted to sound the alarm.

Despite the best efforts of the medical team to treat the infection, her condition collapsed rapidly. She passed away within forty-eight hours of the skin detachment becoming severe. The tragedy of this case lies in the disconnect between the numbers and the reality. The blood tests had shown her disease was under control, leading to a false sense of security. The standard scoring systems used to track lupus activity failed to capture the damage happening in her spinal cord and nerves. When her skin finally gave way, the diagnosis had to be made without a skin biopsy, which is usually required to confirm such a severe reaction, because she was too unstable to undergo the procedure.

This case serves as a stark reminder that in complex diseases like lupus, a normal blood test does not always mean the patient is safe. The disease can shift its focus to areas that standard tests do not monitor, such as the spinal cord and nerves, leaving doctors to rely on clinical observation rather than just lab results. It also highlights the danger of severe skin loss in patients whose immune systems are already suppressed; the usual signs of infection may be absent, making the condition harder to detect until it is too late. The doctors who treated her learned that when a patient with lupus develops a rapidly spreading skin reaction, and drug causes have been carefully ruled out, the disease itself may be the culprit, even if the blood looks calm.